Literature DB >> 6442215

Bacillus subtilis spores as a natural pro-host oral agent. Preliminary data in children.

A Novelli, A Ulivelli, E F Reali, F Mannelli, L Trombi Belcari, R Spezia, P Periti.   

Abstract

The commercial preparation of Bacillus subtilis spores may be considered within the classification of biological response modifiers (BRM's) and included among exogenous natural substances. Recently we decided to study the effect of a long-term B. subtilis spores oral treatment in children suffering from recurrent infectious diseases of the respiratory tract. Fifty-three children 5-9 years old have been studied. The clinical valuative parameter was the number of days of absence from school during a 4-month period. In another group of 12 diseased children, mean age 5.5 yrs we recently initiated a laboratory immunological evaluation of peripheral lymphomonocytes in relation to an oral treatment with B. subtilis spores for at least 2 months. Our results show that B. subtilis spore therapy significantly reduced the frequency of respiratory tract infections in the group of treated children. In addition, preliminary immunological laboratory evaluation demonstrated a complete return to the normal lymphomonocyte status after at least 2 months of treatment with B. subtilis spores.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442215

Source DB:  PubMed          Journal:  Chemioterapia        ISSN: 0392-906X


  4 in total

1.  Molecular characterization and identification of Bacillus clausii Strains marketed for use in oral bacteriotherapy.

Authors:  S Senesi; F Celandroni; A Tavanti; E Ghelardi
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

2.  Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein.

Authors:  Li Li; Xuchu Hu; Zhongdao Wu; Shiqiu Xiong; Zhenwen Zhou; Xiaoyun Wang; Jin Xu; Fangli Lu; Xinbing Yu
Journal:  Parasitol Res       Date:  2009-09-16       Impact factor: 2.289

3.  Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.

Authors:  Delphine Girlich; Roland Leclercq; Thierry Naas; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

4.  Characterization of two Bacillus probiotics.

Authors:  D H Green; P R Wakeley; A Page; A Barnes; L Baccigalupi; E Ricca; S M Cutting
Journal:  Appl Environ Microbiol       Date:  1999-09       Impact factor: 4.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.